Patents may last 20 years on paper, but real market protection for a drug or biologic depends on how you combine patent terms, extensions, and US/EU regulatory exclusivity. This article explains the key building blocks in plain language for life sciences teams.

As billions in drug patents expire, the pharmaceutical industry faces a looming patent cliff. Biotech innovators must rethink IP protection to safeguard revenue and innovation. This article explores trade secrets, continuous filings, data ownership, and regulatory exclusivity, strategies that help companies adapt and thrive beyond patent loss.